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Imatinib mesylate (IM) (Glivec; Novartis, Basel, Switzerland), a tyrosine kinase inhibitor (TKI), has become the standard of care for chronic myeloid 
leukemia (CML).1,2 IM targets BCR-ABL protein, c-kit 
and platelet-derived growth factor receptor. IM is well 
tolerated and has a favorable safety profile.2 Common 
side effects of IM include gastrointestinal disturbanc-
es, fluid retention, skin rashes and myelosuppression. 
Hypopigmentation is an infrequently reported adverse 
effect of IM in CML patients and has been reported in 
small series and case reports, but there are no reports 
from Arab or Saudi patients.
Hypopigmentation of the skin due to IM has been 
reported motly in black patients,3,4 but there are reports 
of skin lightening in Indian patients as well as occa-
sionally in whites.5,6 It was described in an unusually 
high percentage (65%) of Malaysian (mostly ethnically 
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BACKGROUND: hypopigmentation is an infrequently reported adverse effect of imatinib mesylate (im) in 
chronic myeloid leukemia (cml), but there are no reports from arab or saudi patients. thus, we assessed the 
frequency and impact of hypopigmentation in patients with chronic myeloid leukemia (cml) taking im in our 
institution in riyadh.
PATIENTS AND METHODS: We studied 24 adult cml patients taking im and followed from march to June 
2008. telephonic interviews with all the cml patients taking im were conducted and case notes were reviewed. 
findings were confirmed on a subsequent clinic visit by a physician. demographic features, disease status, re-
sponse to im, presence and severity of skin changes and impact of these changes on the patients and the disease 
were noted.
RESULTS: eight (33%) patients (6 males, 2 females) developed hypopigmentation due to im. all patients had 
newly diagnosed, chronic phase cml and received 400 mg im daily. the median age of the affected group was 
37 years (range 18-54 years). hypopigmentation developed during the first 3 months of treatment in 5 patients 
and 6 months or later in 3 patients. it was generalized in 7 patients and involved the hands and face in one 
patient. no photosensitivity was reported and none had other significant side effects.
CONCLUSION: hypopigmentation of the skin can develop in about one third of cml patients taking im. 
physicians taking care of cml patients should be aware of this and patients need to be warned before commenc-
ing im, particularly in dark-skinned patients.
Chinese) CML patients taking IM.7 All of these pa-
tients had accelerated phase or interferon-resistant dis-
ease. These patients had received hydroxyurea previous-
ly, which may have caused skin pigmentation and made 
skin lightening more noticeable subsequently. Sharma 
et al also reported a variable degree of skin lightening 
in 22 of 26 Indian patients and attributed this to the 
darker skin complexion of their patient population.5
IM-induced skin hypopigmentation may have dif-
ferent patterns and may be diffuse or localized to cer-
tain parts of the body; usually exposed areas or vitiligo 
like and patchy.8,9 The frequency and pattern of skin 
involvement appears to be variable in different reports 
and may have a genetic basis.5,7 This unusual side ef-
fect may have important social and psychological 
impacts on patients and needs to be studied in detail 
in different populations. We describe our experience 
brief communicationiMaTiNiB HYPOPiGMeNTaTiON
Hematol Oncol Stem Cell Ther 2(2)     Second Quarter 2009 hemoncstem.edmgr.com 359
with this phenomenon in Saudi patients with CML 
treated with IM.
PATIENTS AND METHODS
Patient notes and physician records on CML patients 
treated with IM, followed at King Khalid University 
Hospital, Riyadh, were reviewed. In addition, telephon-
ic interviews with all the CML patients taking IM were 
conducted from March to June 2008. All patients gave 
informed consent. Patients were asked whether any 
skin lightening was noticed by the patient or the family. 
If the skin changes were noted, details and pattern of 
the hypopigmentation, time of onset and duration after 
start of IM treatment, aggravating factors like sunlight, 
presence of photosensitivity and any further changes 
in the pigmentation level, were inquired about. These 
findings were confirmed and documented by a physi-
cian during subsequent clinic visits. It was not pos-
sible to obtain photographs of the patients before and 
after the IM treatment. Patients were not taking any 
other medication known to be associated with pigment 
changes in the skin. One of the married female patients 
did not become pregnant since the start of IM treat-
ment until the last follow-up. Disease status (phase) at 
the time of diagnosis and at the start of therapy, dose of 
IM, follow-up time and cytogenetic responses were re-
corded from the notes. Patients were considered to have 
a major cytogenetic response if the metaphase analysis 
of bone marrow showed less than 35% Philadelphia 
positive cells. The social impact of the skin change and 
the effect on the patient’s life was also asked about. Skin 
biopsies were not done in any of our patients as they 
were considered unjustified and did not contribute to 
patient management.
RESULTS
Twenty-four adult patients receiving IM for CML were 
evaluated. Eight (33%) patients developed hypopig-
mentation of the skin, including 6 males and 2 females. 
The median age of the affected group was 37 years 
(range 18-54 years) and the median follow-up from 
the start of IM treatment was 15.5 months (range 8-
30 months). All of these patients were in chronic phase 
CML at the time of diagnosis and all received IM, 400 
mg daily. Seven patients had diffuse skin involvement 
with changes more prominent on the face and hands 
in two of these patients. One patient had skin changes 
confined mainly to the face and hands. The majority of 
the patients described the skin changes as moderate, or 
mild to moderate. Five patients (62.5%) developed ob-
servable skin changes during the first three months of 
therapy while 3 patients (37.5%) noticed the changes 
at 6 months or later. Hypopigmentation was persis-
tent, although some patients reported fluctuations in 
the skin color. No photosensitivity was reported and 
patients noticed no changes in the skin related to expo-
sure to the sun, except one patient. There were no other 
significant side effects of IM in any of these patients. All 
of the patients responded to IM with hematological re-
sponse and seven achieved major cytogenetic responses 
(MCR). One patient did not achieve MCR after one 
year of therapy and shifted to a second-line TKI. This 
patient had reversal of skin lightening after stopping 
IM. The social impact on the lives of the patients was 
mostly positive or neutral. Three patients were happy 
(including 2 female patients) while the rest of the pa-
tients reported being indifferent to the changes. None 
of the patients reported embarrassment or depression 
due to the skin changes. Patient characteristics and re-
sults are given in Table 1.
DISCUSSION
In the 5-year follow-up of the International Randomized 
Study of Interferon (IRIS), skin involvement in the IM 
group occurred in 40% of patients.10 In the original 
IRIS trial, these adverse events were reported to be skin 
rashes (most common), pruritus, alopecia and increased 
sweating.11 Hypopigmentation was not reported as a 
separate adverse event in these trials.
Hypopigmentation is more readily noticeable in 
patients with darker skin. As the majority of patients 
in the IM trials were white, this adverse effect was not 
observed frequently except in a few patients of African 
origin. Nevertheless it has been reported in a few white 
patients.6,9 In a report from Malaysia, Leong et al re-
ported the development of skin hypopigmentation in 
65% of their CML patients treated with IM.7 Almost 
all of these patients were ethnically Chinese and had 
interferon-resistant or accelerated phase disease. This 
appears to be an unusually high incidence of this phe-
nomenon, but Sharma et al reported similar results in 
Indian patients.5 
We report our experience in eight CML patients 
treated with IM who developed skin hypopigmentation. 
All of our patients were in chronic phase at the time of 
diagnosis and received the standard dose of IM (400 
mg daily) and did not experience other notable toxicity. 
Tsao et al reported significant additional imatinib toxic-
ity in their patients, which can possibly be explained by 
the higher doses these patients received; 600 mg in 4 
patients and 800 mg in one patient.3
Hypopigmentation is more likely to be observed in 
dark-skinned patients but we observed it in some pa-
tients with fair skin as well. The majority of our patients 
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had generalized skin lightening except one patient who 
developed changes mainly on the face and hands. One 
of our patients who discontinued IM due to poor re-
sponse had reversal of skin lightening. The skin changes 
have been reported to be reversible on discontinuation 
of IM indicating that this effect is not permanent.3
Pathogenesis of skin hypopigmentation by IM is not 
fully understood, but involves the blockade of the c-kit 
(KIT) receptor tyrosine kinase pathway. Receptor c-kit 
and its ligand stem cell factor (SCF) have an important 
role in the homeostasis and in the development and 
survival of melanocytes. C-kit and stem cell factor also 
have an important role in migration of the melanoblasts 
from the neural tube to the skin during embryogene-
sis.12,13 This is supported by the observation that human 
mutations in the encoded tyrosine kinase region of c-
kit cause piebaldism, an autosomal dominant disorder 
characterized by white hair and hypopigmented skin 
patches on the forehead, torso, and extremities.14 In ad-
dition, murine models with human xenograft skin were 
subjected to c-kit inhibitory antibody (K44.2), which 
led to melanocyte loss and a decrease in differentiation 
antigens and melanocyte dendritic processes. Prolonged 
c-kit inhibition led to melanocyte apoptosis.15,16 These 
findings provide evidence of a critical role for SCF/KIT 
in the homeostasis and survival of human melanocytes.
IM inhibits c-kit and by doing so seems to inhibit 
melanocytes, which can very well explain the develop-
ment of hypopigmentation. Why some patients de-
velop hypopigmentation, while others have no effect 
on their skin and whether those patients who do not 
develop skin lightening may be at a higher risk of re-
lapse are unresolved questions. The answer to the first 
question is not known, but may be related to the vari-
able inhibition of relevant tyrosine kinase. Regarding 
the second question, there is no evidence to suggest 
that there are any differences in disease response in 
two groups of patients.
Currently IM is recommended to be continued in-
definitely in responding patients.1 For this reason the 
number of patients taking IM will continue to rise. In 
the future, this is likely to increase the number of pa-
tients who develop skin hypopigmentation. There are 
important psycho-social implications of this phenom-
enon. It may not be acceptable to patients from certain 
racial backgrounds and may cause social embarrassment. 
On the contrary, whitening of the skin may be welcome 
in certain communities. This may render IM for poten-
tial abuse. Particularly patients with dark skin should 
be warned of this adverse effect before commencing IM 
treatment. In our opinion, if hypopigmentation of the 
skin causes significant disturbance to the patient, it may 
be an indication to switch to a second line TKI.
This skin lightening effect of IM may have at least 
one therapeutic potential. Patients with vitiligo and 
patchy hypopigmentation may benefit .17 A generalized 
Table 1.  Patient characteristics and results.
No. age(years) Gender
Time skin 
changes noted 
after start of 
therapy
Dose of imatinib 
(mg)
Severity of skin 
changes (as 
perceived by 
the patients)
Pattern of skin 
involvement MCR
Follow-
up 
(months)
1 26 M 1 M 400 Moderate
Diffuse and 
generalized 
(more prominent 
hands and feet)
No 12
2 37 M 3 M 400 Mild Diffuse and generalized Yes 10
3 25 F 2M 400 Moderate Diffuse and generalized Yes 8
4 18 M 2M 400 Moderate Diffuse and generalized Yes 15
5 38 M 6M 500 Moderate Hands and face Yes 27
6 54 M 6M 400 Mild-moderate Diffuse and generalized Yes 16
7 37 M 3 M 400 Moderate-severe
Diffuse and 
generalized Yes 16
8 42 F >6 month 400 Mild Diffuse and generalized Yes 30
MCR: major cytogenetic response; yrs: years
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hypopigmentation would be useful in these patients to 
make the patchy areas less conspicuous, particularly 
on the exposed parts of the body. As stopping of IM 
usually reverses the hypopigmentation, this treatment 
will need to be taken for long periods. The cost of the 
drug and long-term side effects of IM would be of 
concern in this group of patients. Alternatively, local 
application of an IM skin preparation may be useful 
on the exposed parts of the body and is likely to have 
less side effects. Until trials of systemic or local IM use 
are conducted in these patients, IM can not be recom-
mended for this purpose.
In summary, hypopigmentation of the skin can de-
velop in a significant number of patients taking IM for 
CML. Physicians taking care of CML patients should 
be aware of this, and patients should be warned about 
this adverse effect before commencing IM, particularly 
in dark-skinned patients.
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